摘要：

ology and etiology of Fournier's gangrene: a review of 33 patients. Infection 2009; 37: 306–12. 10 Sorensen MD, Krieger JN, Rivara FP et al. Fournier's Gangrene: population based epidemiology and outcomes. J. Urol. 2009; 181: 2120–6. 11 Sugihara T, Yasunaga H, Horiguchi H et al. Impact of surgical intervention timing on the case fatality rate for Fournier's gangrene: an analysis of 379 cases. BJU Int. 2012; 110: E1096–100. 12 Lauerman MH, Kolesnik O, Sethuraman K et al. Less is more? Antibiotic duration and outcomes in Fournier's gangrene. J. Trauma Acute Care Surg. 2017; 83: 443–8. 13 Chia L, Crum-Cianflone NF. Emergence of multi-drug resistant organisms (MDROs) causing Fournier's gangrene. J. Infect. 2018; 76: 38–43. 14 Aridogan IA, Izol V, Abat D, Karsli O, Bayazit Y, Satar N. Epidemiological characteristics of Fournier's gangrene: a report of 71 patients. Urol. Int. 2012; 89: 457–61. 15 Ayan F, Sunamak O, Paksoy SM et al. Fournier's gangrene: a retrospective clinical study on forty-one patients. ANZ J. Surg. 2005; 75: 1055–8. 16 Ulug M, Gedik E, Girgin S, Celen MK, Ayaz C. The evaluation of microbiology and Fournier's gangrene severity index in 27 patients. Int. J. Infect. Dis. 2009; 13: e424–30. 17 Malik AM, Sheikh S, Pathan R, Khan A, Sheikh U. The spectrum of presentation and management of Fournier's gangrene–an experience of 73 cases. J. Pak. Med. Assoc. 2010; 60: 617–9. 18 Corcoran AT, Smaldone MC, Gibbons EP, Walsh TJ, Davies BJ. Validation of the Fournier's gangrene severity index in a large contemporary series. J. Urol. 2008; 180: 944–8. 19 Erol B, Tuncel A, Hanci V et al. Fournier's gangrene: overview of prognostic factors and definition of new prognostic parameter. Urology 2010; 75: 1193–8. 20 Lin TY, Ou CH, Tzai TS et al. Validation and simplification of Fournier's gangrene severity index. Int. J. Urol. 2014; 21: 696–701. 21 Yilmazlar T, Ozturk E, Ozguc H, Ercan I, Vuruskan H, Oktay B. Fournier's gangrene: an analysis of 80 patients and a novel scoring system. Tech. Coloproctol. 2010; 14: 217–23. 22 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987; 40: 373–83. 23 Bjurlin MA, O'Grady T, Kim DY et al. Causative pathogens, antibiotic sensitivity, resistance patterns, and severity in a contemporary series of Fournier's gangrene. Urology 2013; 81: 752–8. 24 Korkut M, Icoz G, Dayangac M et al. Outcome analysis in patients with Fournier's gangrene: report of 45 cases. Dis. Colon Rectum 2003; 46: 649–52. 25 Voelzke BB, Hagedorn JC. Presentation and diagnosis of Fournier Gangrene. Urology 2018; 114: 8–13. 26 Tenorio CEL, Lima SVC, Albuquerque AV, Cavalcanti MP, Teles F. Risk factors for mortality in fournier's gangrene in a general hospital: use of simplified founier gangrene severe index score (SFGSI). Int. Braz. J. Urol. 2018; 44: 95–101. 27 Skendzel LP, Youden WJ. Systematic versus random error in laboratory surveys. Am. J. Clin. Pathol. 1970; 54: 448–50. 28 Doluoglu OG, Karagoz MA, Kilinc MF et al. Overview of different scoring systems in Fournier's gangrene and assessment of prognostic factors. Turk. J. Urol. 2016; 42: 190–6. 29 Boyer A, Vargas F, Coste F et al. Influence of surgical treatment timing on mortality from necrotizing soft tissue infections requiring intensive care management. Intensive Care Med. 2009; 35: 847–53. 30 Chao WN, Tsai CF, Chang HR et al. Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis. Am. J. Surg. 2013; 206: 32–9.

展开